FDA approves first drug for full range of narcolepsy symptoms
medicalxpress - The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults. Orzeyful marks the first medication approved for the full range of symptoms associated with narcolepsy type 1 and is the first approved…
AI Summary: The FDA has approved a medication that treats the full range of narcolepsy symptoms, including excessive daytime sleepiness and cataplexy, marking the first such comprehensive option for patients with narcolepsy type 1. Clinicians now have a single, regulated choice to address multiple debilitating symptoms rather than juggling piecemeal therapies.
Related Stories
Drug-induced hibernation shows promise to limit stroke brain injury / 2 months
Mid‑stage Parkinson trial failure halts drug development plans / 3 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 3 months
FDA escalates push to withdraw Amgen’s Tavneos; Amgen updates label / 3 months
Denali drug receives accelerated approval for rare CNS indication / 5 months
FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 5 months
First-in-human trial primes immune system to accept donor livers / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Digital Health, Biotech, Hearing Loss, FDA and look for the RSS link.
StackHealth Time Machine